Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.74% | -109.98% | -16.50% | -6.67% | -11.29% |
| Total Depreciation and Amortization | 92.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.12% | 5,243.58% | 382.08% | -42.51% | -60.88% |
| Change in Net Operating Assets | 217.72% | -251.94% | 662.42% | -118.27% | 21.98% |
| Cash from Operations | 23.24% | -9.52% | 3.43% | -30.71% | -12.33% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 154.35% | -1,634.45% | -0.67% | 176.79% | -56.54% |
| Cash from Investing | 154.32% | -1,634.45% | -0.67% | 176.79% | -56.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 54,671.70% | -94.34% | 708.25% | 79,420.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | 77.92% |
| Cash from Financing | -- | 54,671.70% | -94.39% | 784.01% | 365.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -69.50% | 2,657.63% | -396.41% | 110.76% | -19.59% |